» Articles » PMID: 19165322

Immunization with Single-cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV(mac)239

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2009 Jan 24
PMID 19165322
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4(+) T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIV(mac)239. However, significantly lower viral loads and higher memory CD4(+) T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIV(mac)239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV.

Citing Articles

The Impact and Effects of Host Immunogenetics on Infectious Disease Studies Using Non-Human Primates in Biomedical Research.

Berry N, Mee E, Almond N, Rose N Microorganisms. 2024; 12(1).

PMID: 38257982 PMC: 10818626. DOI: 10.3390/microorganisms12010155.


Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Manoharan V, Khattar S, LaBranche C, Montefiori D, Samal S Sci Rep. 2018; 8(1):8952.

PMID: 29895833 PMC: 5997738. DOI: 10.1038/s41598-018-27433-x.


High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Ita S, Hill A, Lam E, Dufort F, Yang X, Newman R J Virol. 2018; 92(7).

PMID: 29343575 PMC: 5972902. DOI: 10.1128/JVI.01574-17.


Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.

Berry N, Manoussaka M, Ham C, Ferguson D, Tudor H, Mattiuzzo G PLoS Pathog. 2016; 12(12):e1006083.

PMID: 28002473 PMC: 5176322. DOI: 10.1371/journal.ppat.1006083.


Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV Infection.

Adnan S, Reeves R, Gillis J, Wong F, Yu Y, Camp J PLoS Pathog. 2016; 12(12):e1006104.

PMID: 27959961 PMC: 5189958. DOI: 10.1371/journal.ppat.1006104.


References
1.
Johnson W, Sanford H, Schwall L, Burton D, Parren P, Robinson J . Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol. 2003; 77(18):9993-10003. PMC: 224602. DOI: 10.1128/jvi.77.18.9993-10003.2003. View

2.
Rollman E, Smith M, Brooks A, Purcell D, Zuber B, Ramshaw I . Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol. 2007; 179(7):4571-9. DOI: 10.4049/jimmunol.179.7.4571. View

3.
Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M . Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med. 2004; 199(12):1709-18. PMC: 2212812. DOI: 10.1084/jem.20040432. View

4.
Wilson N, Reed J, Napoe G, Piaskowski S, Szymanski A, Furlott J . Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006; 80(12):5875-85. PMC: 1472612. DOI: 10.1128/JVI.00171-06. View

5.
Kuroda M, Schmitz J, Barouch D, Craiu A, Allen T, Sette A . Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med. 1998; 187(9):1373-81. PMC: 2212269. DOI: 10.1084/jem.187.9.1373. View